Seven additional phase 3 trials for retatrutide are expected to wrap up in 2026
Session 7: Small Group Working Sessions Day 2 Format: Interactive Working Sessions Around a Roundtable (In-Person Only) In this interactive and collaborative session, in-person attendees will participate in focused discussions on key topics from Day 2, including oral formulation challenges, device design considerations, human factors study approaches, and combination product development strategies
This review seeks to highlight emerging evidence that suggests a growing benefit of GLP-1 RAs irrespective of T2DM status in coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and blood pressure
Allusose does not spike blood glucose levels and delays carb absorption
This back-and-forth cycle can easily add weeks to your timeline, frustrating both patients and healthcare providers working to access the most effective treatment available